Howard M. Sandler, MD, on Prostate Cancer: Results From RTOG 0415
2015 ASTRO Annual Meeting
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses this phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).
Alysa M. Fairchild, MD
Alysa M. Fairchild, MD, of the Cross Cancer Institute and the University of Alberta, discusses her study on the use of dexamethasone to reduce pain flare in patients receiving palliative radiotherapy for bone metastases (Abstract LBA6663).
Vratislav Strnad, MD, PhD
Vratislav Strnad, MD, PhD, of the University Hospital in Erlangen, discusses results from a European study comparing accelerated partial-breast irradiation using brachytherapy, to the standard treatment of whole-breast irradiation for women with low-risk breast cancer (Abstract LBA7).
Stephen G. Chun, MD
Stephen G. Chun, MD, of MD Anderson Cancer Center, discusses the comparison of 3D conformal and IMRT outcomes for locally advanced non-small cell lung cancer (Abstract 2).
Howard M. Sandler, MD
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses how adding 24 months of daily antiandrogen therapy during and after radiotherapy was shown to significantly improve long-term overall survival following prostate cancer recurrence after a radical prostatectomy (Abstract LBA5).
Samuel Chao, MD
Samuel Chao, MD, of Cleveland Clinic, discusses the QMAP program and data-driven management, which offer ways to improve consistency and drive quality in radiation oncology departments (Abstract 39).